Skip to main content

Table 3 Concentrations of pneumococcal polysaccharide antigen serotype-specific IgG antibodies and opsonization indices in the RA treatment groups before and after 23-valent pneumococcal polysaccharide vaccination

From: Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients

   RA Control MTX group ABT/MTX group
n = 35 n = 55 n = 15
IgG GMCs (μg/ml)
6B Before 0.84(0.58 to 1.11) 1.42(0.86 to 1.97) 1.19(0.73 to 1.65)
  After 4.05(2.13 to 5.97)* 4.36(2.17 to 6.55)* 2.49(0.29 to 4.70)
  Fold increase 2.38(1.41 to 5.62) 1.75(1.15 to 3.11) 1.19(0.77 to 2.44)
23F Before 1.17(0.85 to 1.48) 1.79(1.33 to 2.25) 1.17(0.63 to 1.71)
  After 11.61(4.16 to 19.07)* 7.41(4.48 to 10.33)* 3.78(1.87 to 5.70)*
  Fold increase 3.36(1.85 to 9.42) 2.00(1.27 to 5.48) 1.96(1.15 to 5.99)
GM-OIs
6B Before 17.24(10.96 to 23.53) 150.79(14.85 to 286.74) 43.33(0.15 to 86.51)
  After 981.15(407.24 to 1555.05)* 584.29(270.29 to 898.28)* 1454.80(109.29 to 2800.31)*
  Fold increase 10.22(1.92 to 79.48) 2.57(1.22 to 22.40) 14.65(2.96 to 193.79)
23F Before 63.21(−6.79 to 133.20) 52.11(14.04 to 90.18) 178.13(−130.27 to 486.54)
  After 713.49(307.97 to 1119.01)* 724.56(336.93 to 1112.19)* 880.73(−81.54 to 1843.01)*
  Fold increase 6.86(2.50 to 27.14) 3.75(1.47 to 38.32) 2.50(1.33 to 35.74)
  1. IgG GMCs and GM-OIs are expressed as the mean (95 % CI). Fold increases are expressed as the median (IQR). Differences between pre- and post-vaccination GMCs of serotype-specific IgG were assessed using a paired-sample t test
  2. RA rheumatoid arthritis, MTX methotrexate, ABT abatacept, GMC geometric mean concentration, GM-OI geometric mean opsonization index, CI, confidence interval, IQR interquartile index
  3. *p < 0.05 compared with pre-vaccination IgG GMCs or GM-OIs